Pacira Pharmaceuticals Inc (NASDAQ:PCRX) CEO David M. Stack sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $47.39, for a total transaction of $710,850.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

NASDAQ:PCRX opened at $46.73 on Thursday. Pacira Pharmaceuticals Inc has a 52 week low of $26.95 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83. The company has a market cap of $1.89 billion, a P/E ratio of -80.57, a PEG ratio of 78.77 and a beta of 1.68.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.40. The business had revenue of $83.45 million during the quarter, compared to analysts’ expectations of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The business’s quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter last year, the company posted $0.11 earnings per share. As a group, equities analysts anticipate that Pacira Pharmaceuticals Inc will post 0.02 EPS for the current fiscal year.

A number of research firms have recently issued reports on PCRX. Piper Jaffray Companies set a $55.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Needham & Company LLC set a $60.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. JMP Securities increased their price objective on shares of Pacira Pharmaceuticals from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, November 1st. HC Wainwright increased their price objective on shares of Pacira Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Friday, November 2nd. Finally, Mizuho increased their price objective on shares of Pacira Pharmaceuticals to $46.00 and gave the company a “neutral” rating in a research note on Monday, November 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $53.76.

Several hedge funds and other institutional investors have recently bought and sold shares of PCRX. Royal Bank of Canada increased its stake in shares of Pacira Pharmaceuticals by 93.3% in the first quarter. Royal Bank of Canada now owns 26,472 shares of the company’s stock worth $825,000 after acquiring an additional 12,776 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in Pacira Pharmaceuticals during the second quarter valued at $219,000. Pendal Group Ltd grew its position in Pacira Pharmaceuticals by 9.3% during the second quarter. Pendal Group Ltd now owns 23,326 shares of the company’s stock valued at $748,000 after buying an additional 1,975 shares during the period. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Pacira Pharmaceuticals during the second quarter valued at $312,000. Finally, Rice Hall James & Associates LLC grew its position in Pacira Pharmaceuticals by 3.7% during the second quarter. Rice Hall James & Associates LLC now owns 338,032 shares of the company’s stock valued at $10,834,000 after buying an additional 12,161 shares during the period.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Pacira Pharmaceuticals Inc (PCRX) CEO Sells $710,850.00 in Stock” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/11/22/insider-selling-pacira-pharmaceuticals-inc-pcrx-ceo-sells-710850-00-in-stock.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.